What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve This study aims to evaluate the potential role of macrophage migration inhibitory factor (MIF) as a plasma biomarker in cerebral small vessel disease with cognitive impairment (CSVD-CI). Specifically, the study attempts to address the following issues: 1. **Differences in MIF Levels**: Whether there are significant differences in plasma MIF levels between healthy controls (HC), CSVD-CI patients, and CSVD patients with normal cognition (CSVD-CN). 2. **Relationship Between MIF and Cognitive Function**: Whether plasma MIF levels in CSVD-CI patients are significantly correlated with various cognitive assessment scores, plasma blood-brain barrier (BBB) related indicators, white matter hyperintensity (WMH) Fazekas scores, and right superior temporal gyrus low-frequency fluctuation amplitude (mALFF) values. 3. **Potential of MIF as a Diagnostic Marker**: Whether plasma MIF levels can serve as a potential biomarker for early identification of CSVD-CI, and whether constructing composite markers can improve diagnostic accuracy. ### Research Background Cerebral small vessel disease (CSVD) is a common cause of vascular cognitive impairment in the elderly and is associated with progressive cognitive decline. Although previous studies have shown that imaging markers of CSVD-CI (such as white matter hyperintensities) are related to cognitive impairment, there is currently a lack of sensitive and accurate biomarkers for precise diagnosis of CSVD-CI. MIF, as a protein involved in inflammation and immune response, may play an important role in the pathology of CSVD-CI, making it significant to explore its potential as a biomarker. ### Research Methods - **Participants**: The study recruited 54 healthy controls, 60 CSVD-CI patients, and 57 CSVD-CN patients. - **Assessment Methods**: All participants underwent neuropsychological assessments and multimodal magnetic resonance imaging examinations. Plasma MIF levels were measured using enzyme-linked immunosorbent assay (ELISA). - **Statistical Analysis**: The least absolute shrinkage and selection operator (LASSO) model was used to determine composite markers, and their diagnostic performance was evaluated through receiver operating characteristic (ROC) analysis. ### Main Findings 1. **Differences in MIF Levels**: Plasma MIF levels in CSVD-CI patients were significantly higher than those in healthy controls and CSVD-CN patients. 2. **Relationship Between MIF and Cognitive Function**: In CSVD-CI patients, plasma MIF levels were significantly correlated with multiple cognitive assessment scores, plasma BBB-related indicators, WMH Fazekas scores, and right superior temporal gyrus mALFF values. 3. **Potential of MIF as a Diagnostic Marker**: Plasma MIF levels showed high accuracy (>80%) in distinguishing CSVD-CI patients from CSVD-CN patients or healthy controls. Composite markers (including plasma MIF) achieved accuracy exceeding 80% in distinguishing CSVD-CI patients from CSVD-CN patients or healthy controls. ### Conclusion This study demonstrates that plasma MIF levels are significantly elevated in CSVD-CI patients and are associated with poorer cognitive performance. Plasma MIF may mediate cognitive decline in CSVD through BBB dysfunction, WMH changes, and alterations in brain activity. As a potential peripheral biomarker, plasma MIF can provide satisfactory discriminative ability for identifying CSVD patients. Particularly, combining plasma MIF with other imaging markers can achieve sensitive and accurate diagnosis of CSVD-CI.

Macrophage Migration Inhibitory Factor as a Potential Plasma Biomarker of Cognitive Impairment in Cerebral Small Vessel Disease

Aggregation of Vascular Risk Factors Modulates the Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment Patients

The Relevance of Serum Macrophage Migration Inhibitory Factor Level and Executive Function in Patients with White Matter Hyperintensity in Cerebral Small Vessel Disease

The relevance of serum macrophage migratory inhibitory factor and cognitive dysfunction in patients with cerebral small vascular disease

Identification of Inflammatory and Vascular Markers Associated with Mild Cognitive Impairment.

Quantitative assessments of white matter hyperintensities and plasma biomarkers can predict cognitive impairment and cerebral microbleeds in cerebral small vessel disease patients

Neurovascular coupling, functional connectivity, and cerebrovascular endothelial extracellular vesicles as biomarkers of mild cognitive impairment

Macrophage migration inhibitor factor (MIF): Potential role in cognitive impairment disorders

Potential Association of Neutrophil Extracellular Traps with Cognitive Impairment in Cerebral Small Vessel Disease.

Inflammatory biomarkers and cerebral small vessel disease: a community-based cohort study

Correlations of Plasma Biomarkers and Imaging Characteristics of Cerebral Small Vessel Disease

Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment

Deep Microbleeds and Periventricular White Matter Disintegrity Are Independent Predictors of Attention/executive Dysfunction in Non-Dementia Patients with Small Vessel Disease.

Cerebrospinal fluid macrophage migration inhibitory factor: a potential predictor of cerebral vasospasm and clinical outcome after aneurysmal subarachnoid hemorrhage

Identification of differentially expressed exosome proteins in serum as potential biomarkers for cognitive impairments in cerebral small vessel disease

Biomarkers Involved in the Pathogenesis of Cerebral Small-Vessel Disease

Increased Plasma Levels of Macrophage Migration Inhibitory Factor in a Transgenic Mouse Model of Alzheimer’s Disease

Plasma Lipoprotein-Associated Phospholipase A2 and Superoxide Dismutase Are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment

The Association Between Glymphatic System Dysfunction and Cognitive Impairment in Cerebral Small Vessel Disease

Changes in Multiparametric Magnetic Resonance Imaging and Plasma Amyloid-Beta Protein in Subjective Cognitive Decline

A Clinical Study of Blood Inflammatory Markers in Patients with Vascular Cognitive Impairment no Dementia